{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:22:06Z","timestamp":1760908926402},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,12,30]],"date-time":"2014-12-30T00:00:00Z","timestamp":1419897600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s00280-014-2665-8","type":"journal-article","created":{"date-parts":[[2014,12,29]],"date-time":"2014-12-29T10:53:19Z","timestamp":1419850399000},"page":"457-464","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival"],"prefix":"10.1007","volume":"75","author":[{"given":"Akiyoshi","family":"Kasuga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Okano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Naruge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuko","family":"Takasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumio","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,30]]},"reference":[{"issue":"6","key":"2665_CR1","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris III","year":"1997","unstructured":"Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403\u20132413","journal-title":"J Clin Oncol"},{"issue":"15","key":"2665_CR2","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"MJ Moore","year":"2007","unstructured":"Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25(15):1960\u20131966. doi: 10.1200\/jco.2006.07.9525","journal-title":"J Clin Oncol"},{"issue":"18","key":"2665_CR3","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Hoff Von","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691\u20131703. doi: 10.1056\/NEJMoa1304369","journal-title":"N Engl J Med"},{"issue":"13","key":"2665_CR4","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","volume":"31","author":"H Ueno","year":"2013","unstructured":"Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Sho M, Kitano M, Cheng AL, Mizumoto K, Chen JS, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato A, Ohashi Y, Okusaka T, Tanaka M (2013) Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST Study. J Clin Oncol 31(13):1640\u20131648. doi: 10.1200\/jco.2012.43.3680","journal-title":"J Clin Oncol"},{"issue":"19","key":"2665_CR5","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817\u20131825. doi: 10.1056\/NEJMoa1011923","journal-title":"N Engl J Med"},{"issue":"2","key":"2665_CR6","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00280-008-0741-7","volume":"63","author":"C Morizane","year":"2009","unstructured":"Morizane C, Okusaka T, Furuse J, Ishii H, Ueno H, Ikeda M, Nakachi K, Najima M, Ogura T, Suzuki E (2009) A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol 63(2):313\u2013319. doi: 10.1007\/s00280-008-0741-7","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"2665_CR7","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s00280-011-1786-6","volume":"69","author":"C Morizane","year":"2012","unstructured":"Morizane C, Okusaka T, Ueno H, Kondo S, Ikeda M, Furuse J, Shinichi O, Nakachi K, Mitsunaga S, Kojima Y, Suzuki E, Ueno M, Yamaguchi T (2012) Phase I\/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients. Cancer Chemother Pharmacol 69(4):957\u2013964. doi: 10.1007\/s00280-011-1786-6","journal-title":"Cancer Chemother Pharmacol"},{"issue":"18","key":"2665_CR8","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1200\/JCO.2003.09.140","volume":"21","author":"M Tempero","year":"2003","unstructured":"Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J (2003) Randomized phase II comparison of dose-intense gemcitabine: 30-min infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21(18):3402\u20133408. doi: 10.1200\/jco.2003.09.140","journal-title":"J Clin Oncol"},{"issue":"23","key":"2665_CR9","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1200\/JCO.2008.20.9007","volume":"27","author":"E Poplin","year":"2009","unstructured":"Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O\u2019Dwyer P, Haller D, Catalano P, Cella D, Benson AB 3rd (2009) Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-min infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27(23):3778\u20133785. doi: 10.1200\/jco.2008.20.9007","journal-title":"J Clin Oncol"},{"issue":"6","key":"2665_CR10","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.bjc.6601242","volume":"89","author":"LM Forrest","year":"2003","unstructured":"Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ (2003) Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 89(6):1028\u20131030. doi: 10.1038\/sj.bjc.6601242","journal-title":"Br J Cancer"},{"issue":"4","key":"2665_CR11","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/sj.bjc.6606087","volume":"104","author":"MJ Proctor","year":"2011","unstructured":"Proctor MJ, Morrison DS, Talwar D, Balmer SM, O\u2019Reilly DS, Foulis AK, Horgan PG, McMillan DC (2011) An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer 104(4):726\u2013734. doi: 10.1038\/sj.bjc.6606087","journal-title":"Br J Cancer"},{"issue":"11","key":"2665_CR12","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.ejca.2011.04.011","volume":"47","author":"U Pelzer","year":"2011","unstructured":"Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dorken B, Riess H, Oettle H (2011) Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 47(11):1676\u20131681. doi: 10.1016\/j.ejca.2011.04.011","journal-title":"Eur J Cancer"},{"issue":"2","key":"2665_CR13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00280-010-1311-3","volume":"67","author":"K Sudo","year":"2011","unstructured":"Sudo K, Yamaguchi T, Nakamura K, Denda T, Hara T, Ishihara T, Yokosuka O (2011) Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer. Cancer Chemother Pharmacol 67(2):249\u2013254. doi: 10.1007\/s00280-010-1311-3","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"2665_CR14","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/jjco\/hyq005","volume":"40","author":"A Todaka","year":"2010","unstructured":"Todaka A, Fukutomi A, Boku N, Onozawa Y, Hironaka S, Yasui H, Yamazaki K, Taku K, Machida N, Sakamoto T, Tomita H (2010) S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure. Jpn J Clin Oncol 40(6):567\u2013572. doi: 10.1093\/jjco\/hyq005","journal-title":"Jpn J Clin Oncol"},{"issue":"3\u20134","key":"2665_CR15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000127413","volume":"73","author":"S Boeck","year":"2007","unstructured":"Boeck S, Wilkowski R, Bruns CJ, Issels RD, Schulz C, Moosmann N, Laessig D, Haas M, Golf A, Heinemann V (2007) Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. Oncology 73(3\u20134):221\u2013227. doi: 10.1159\/000127413","journal-title":"Oncology"},{"issue":"5","key":"2665_CR16","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s00280-013-2278-7","volume":"72","author":"N Takahara","year":"2013","unstructured":"Takahara N, Isayama H, Nakai Y, Sasaki T, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Kogure H, Yamamoto N, Sasahira N, Hirano K, Ijichi H, Tateishi K, Tada M, Koike K (2013) A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer. Cancer Chemother Pharmacol 72(5):985\u2013990. doi: 10.1007\/s00280-013-2278-7","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5\u20136","key":"2665_CR17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000329803","volume":"80","author":"E Assaf","year":"2011","unstructured":"Assaf E, Verlinde-Carvalho M, Delbaldo C, Grenier J, Sellam Z, Pouessel D, Bouaita L, Baumgaertner I, Sobhani I, Tayar C, Paul M, Culine S (2011) 5-fluorouracil\/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology 80(5\u20136):301\u2013306. doi: 10.1159\/000329803","journal-title":"Oncology"},{"issue":"4","key":"2665_CR18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000356158","volume":"59","author":"MG Lee","year":"2013","unstructured":"Lee MG, Lee SH, Lee SJ, Lee YS, Hwang JH, Ryu JK, Kim YT, Kim DU, Woo SM (2013) 5-Fluorouracil\/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy. Chemotherapy 59(4):273\u2013279. doi: 10.1159\/000356158","journal-title":"Chemotherapy"},{"issue":"11","key":"2665_CR19","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/jjco\/hyn098","volume":"38","author":"T Tanaka","year":"2008","unstructured":"Tanaka T, Ikeda M, Okusaka T, Ueno H, Morizane C, Hagihara A, Iwasa S, Kojima Y (2008) Prognostic factors in Japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy. Jpn J Clin Oncol 38(11):755\u2013761. doi: 10.1093\/jjco\/hyn098","journal-title":"Jpn J Clin Oncol"},{"issue":"3\u20134","key":"2665_CR20","first-page":"175","volume":"80","author":"JH Yi","year":"2011","unstructured":"Yi JH, Lee J, Park SH, Lee KT, Lee JK, Lee KH, Choi DW, Choi SH, Heo JS, Lim do H, Park YS, Lim HY, Kang WK, Park K, Park JO (2011) A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer. Oncology 80(3\u20134):175\u2013180. doi: 10.1159\/000328449","journal-title":"Oncology"},{"issue":"6","key":"2665_CR21","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1159\/000321014","volume":"56","author":"M Shimoda","year":"2010","unstructured":"Shimoda M, Katoh M, Kita J, Sawada T, Kubota K (2010) The Glasgow prognostic score is a good predictor of treatment outcome in patients with unresectable pancreatic cancer. Chemotherapy 56(6):501\u2013506. doi: 10.1159\/000321014","journal-title":"Chemotherapy"},{"issue":"5","key":"2665_CR22","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1159\/000094562","volume":"6","author":"P Glen","year":"2006","unstructured":"Glen P, Jamieson NB, McMillan DC, Carter R, Imrie CW, McKay CJ (2006) Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology 6(5):450\u2013453. doi: 10.1159\/000094562","journal-title":"Pancreatology"},{"issue":"9","key":"2665_CR23","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1245\/s10434-012-2348-9","volume":"19","author":"M Torre La","year":"2012","unstructured":"La Torre M, Nigri G, Cavallini M, Mercantini P, Ziparo V, Ramacciato G (2012) The Glasgow prognostic score as a predictor of survival in patients with potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol 19(9):2917\u20132923. doi: 10.1245\/s10434-012-2348-9","journal-title":"Ann Surg Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2665-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2665-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2665-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,18]],"date-time":"2019-08-18T22:11:00Z","timestamp":1566166260000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2665-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,30]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["2665"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2665-8","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,30]]}}}